Since the loss of HK2 led to a reduction in glycolysis and a compensatory upregulation of oxidative phosphorylation, we hypothesized that targeting both metabolic pathways could potentially be therapeutic for HCC. Here, HK2 is linked to hepatocellular carcinoma.